Vertex Pharmaceuticals Sees 10.78 Billion Turnover Surge to Top 85 Stocks by Volume Despite Stock Price Decline

On March 31, 2025, Vertex Pharmaceuticals (VRTX) experienced a significant trading day with a turnover of 10.78 billion, marking a 70.04% increase from the previous day. This surge placed Vertex among the top 85 stocks by trading volume for the day. However, the stock price of Vertex Pharmaceuticals declined by 1.60%, marking the second consecutive day of losses, with a total decrease of 3.53% over the past two days.

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device. This decision follows clinical trials that failed to meet efficacy goals. Despite this setback, the company continues to advance zimislecel, another potential treatment for severe type 1 diabetes, under the new name VX-880.

Vertex Pharmaceuticals has provided updates on its type 1 diabetes portfolio, highlighting the discontinuation of VX-264 due to its inability to meet clinical efficacy targets. The company remains committed to advancing zimislecel, a promising treatment for severe type 1 diabetes, which has been renamed VX-880.